论文部分内容阅读
[目的]研究血清VEGFR-2浓度变化与肝癌患者经肝动脉化疗栓塞术(TACE)治疗后近期疗效的相关性。[方法]采用ELISA方法检测24例晚期肝癌患者TACE治疗前后血清VEGFR-2的表达水平,并分析VEGFR-2浓度变化与晚期肝癌患者临床病理的关系。[结果 ]血清VEGFR-2浓度与肿瘤数目、肝硬化病史有关(P<0.05);PFS与肿瘤数目、门脉癌栓、肿瘤大小、肝硬化有关(P<0.05)。治疗1个月后疾病缓解5例,疾病稳定14例,疾病进展5例,m PFS分别为7.84、4.78、3.68个月(P<0.05)。[结论]TACE术后1个月血清VEGFR-2浓度变化与PFS有关,血清VEGFR-2浓度变化可能成为肝癌TACE治疗潜在的近期疗效预测指标。
[Objective] To investigate the relationship between the change of serum VEGFR-2 concentration and the short-term curative effect of transcatheter arterial chemoembolization (TACE) in patients with liver cancer. [Methods] The serum levels of VEGFR-2 in 24 patients with advanced hepatocellular carcinoma before and after TACE treatment were detected by ELISA. The relationship between the changes of VEGFR-2 concentration and the clinicopathological features of patients with advanced hepatocellular carcinoma was analyzed. [Results] The serum VEGFR-2 concentration was correlated with the number of tumors and the history of liver cirrhosis (P <0.05). PFS was related to the number of tumor, portal vein tumor thrombus, tumor size and cirrhosis (P <0.05). Five months after treatment, 5 cases were relieved of disease, 14 cases were stable and 5 cases were disease progression. The m PFS were 7.84, 4.78 and 3.68 respectively (P <0.05). [Conclusion] The change of serum VEGFR-2 level at 1 month after TACE is related to PFS. The change of serum VEGFR-2 level may be a potential predictor of TACE for hepatocellular carcinoma.